Profilo
Gilbert Wagener is currently the Chief Medical Officer at Pharnext SA since 2023.
Prior to this, he held the same position at Cell2B - Advanced Therapeutics SA and Ixaka Ltd. Dr. Wagener holds a doctorate from Erasmus University Rotterdam and Philipps University of Marburg, and an MBA from the University of Basel.
Posizioni attive di Gilbert Wagener
| Società | Posizione | Inizio |
|---|---|---|
| PHARNEXT SCA | Direttore Tecnico/Scientifico/R&S | 15/06/2023 |
Precedenti posizioni note di Gilbert Wagener
| Società | Posizione | Fine |
|---|---|---|
Ixaka Ltd.
Ixaka Ltd. BiotechnologyHealth Technology Operates as a preclinical-stage immunotherapy biotech company | Direttore Tecnico/Scientifico/R&S | - |
Cell2B - Advanced Therapeutics SA
Cell2B - Advanced Therapeutics SA BiotechnologyHealth Technology Develops stem cell therapies and pharmaceuticals | Direttore Tecnico/Scientifico/R&S | - |
Formazione di Gilbert Wagener
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 6 |
|---|---|
Erasmus University Rotterdam
Erasmus University Rotterdam Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Basel
University of Basel Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Philipps University of Marburg
Philipps University of Marburg Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Pharnext SA
Pharnext SA Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops therapies for patients to treat neurodegenerative diseases | Health Technology |
Cell2B - Advanced Therapeutics SA
Cell2B - Advanced Therapeutics SA BiotechnologyHealth Technology Develops stem cell therapies and pharmaceuticals | Health Technology |
Ixaka Ltd.
Ixaka Ltd. BiotechnologyHealth Technology Operates as a preclinical-stage immunotherapy biotech company | Health Technology |
















